← All Inhibikase Therapeutics, INC filings

Inhibikase Therapeutics, INC 8-K filings

NASDAQ
IKT
Inhibikase Therapeutics, INC
8-K/A: Inhibikase Therapeutics Appoints New CFO, Details Compensation Package
Inhibikase Therapeutics has amended its previous 8-K filing to disclose the compensation details for newly appointed Chief Financial Officer, Garth Lees-Rolfe, effective April 1, 2024.
NASDAQ
IKT
Inhibikase Therapeutics, INC
8-K: Inhibikase Therapeutics Announces Positive Preliminary Outcomes from FDA Pre-NDA Meeting for IkT-001Pro
Inhibikase Therapeutics reports positive preliminary feedback from the FDA regarding the approval pathway for its drug candidate IkT-001Pro in blood and gastrointestinal cancers.
NASDAQ
IKT
Inhibikase Therapeutics, INC
8-K: Inhibikase Therapeutics Announces At-The-Market Offering of up to $5.66 Million in Common Stock
Inhibikase Therapeutics has entered into an agreement to sell up to $5.66 million of its common stock through an at-the-market offering.
NASDAQ
IKT
Inhibikase Therapeutics, INC
8-K: Inhibikase Therapeutics Announces CFO Retirement and Successor
Inhibikase Therapeutics has announced the retirement of its Chief Financial Officer, Joseph Frattaroli, effective at the end of the first quarter of 2024, and the appointment of Garth Lees-Rolfe as his successor.